Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Impact of prior inotuzumab ozogamicin treatment on brexucabtagene autoleucel outcomes in adults with B-cell ALL
Aldoss, Ibrahim , Roloff, Gregory W. , Kopmar, Noam E. , Lin, Chenyu , Advani, Anjali S. , Dekker, Simone E. , O’Connor, Timothy E. , Jeyakumar, Nikeshan , Muhsen, Ibrahim N. , Valtis, Yannis K. , Zhang, Amy , Miller, Katharine, Sutherland, Katherine C. , Ahmed, Mohamed , Zambrano, Héctor, Bradshaw, Danielle , Schwartz, Marc S. , Tracy, Sean , Kubiak, Michal Jakub , Mukherjee, Akash , Mountjoy, Luke , Malik, Shahbaz A. , Shaughnessy, Paul , Ladha, Abdullah , Stefan, Maryann, Guzowski, Caitlin, Hoeg, Rasmus T. , Moore, Jozal , Connor, Matthew P. , O’Dwyer, Kristen M. , Hill, LaQuisa C. , Tsai, Stephanie B., Sasine, Joshua , Solh, Melhem , Koura, Divya, Veeraputhiran, Muthu, Blunk, Betsy, Oliai, Caspian , Park, Jae H. , Bachanová, Veronika , Galal, Ahmed , Bishop, Michael R. , Pullarkat, Vinod , Muffly, Lori , Lin, Chenyu , Advani, Anjali S , Jeyakumar, Nikeshan , Dykes, Kaitlyn C , Chen, Evan , Bradshaw, Danielle , Dholaria, Bhagirathbhai R , Majhail, Navneet S , Logan, Aaron C , Ladha, Abdullah , Hilal, Talal , Moore, Jozal , Connor, Matthew , Hill, LaQuisa C , Sasine, Joshua , Lee, Catherine J , Leonard, Jessica T , Frey, Noelle V , Luskin, Marlise R , Muffly, Lori , Bachanova, Veronika , Aldoss, Ibrahim , Muhsen, Ibrahim N , Sutherland, Katherine , Roloff, Gregory W , Faramand, Rawan , Gupta, Vishal , Dykes, Kaitlyn C. , Mercadal, Santiago , Schwartz, Marc, Dholaria, Bhagirathbhai , Majhail, Navneet S. , Battiwalla, Minoo , Mathews, John, Hilal, Talal , O'Dwyer, Kristin , Tsai, Stephanie B., Kota, Vamsi , Oliai, Caspian H , Frey, Noelle V. , Bishop, Michael Russell , Stock, Wendy , Cassaday, Ryan D. , Shah, Bijal

Mayo Clinic

Blood Advances | August 2, 2024 | Volume: 8 | Issue: 23 | Pages: 6139-6147

10.1182/bloodadvances.2024013747 | PMID 39093952 Get It

Abstract The effect of prior inotuzumab ozogamicin (InO) treatment on brexucabtagene autoleucel (brexu-cel) outcomes remains unclear in adults with acute lymphoblastic leukemia (ALL). We conducted a retrospective multicenter analysis of 189 patients with relapsed/refractory ALL treated with brexu-cel. Over half of the patients received InO before brexu-cel (InO exposed). InO-exposed patients were more heavily pretreated (P = .02) and frequently had active marrow disease before apheresis (P = .03). Response rate and toxicity profile after brexu-cel were comparable for InO-exposed and InO-naïve patients; however, consolidation therapy after brexu-cel response was used at a higher rate in InO-naïve patients (P = .005). With a median follow-up of 11.4 months, InO-exposed patients had inferior progression-free survival (PFS; P = .013) and overall survival (OS; P = .006) in univariate analyses; however, prior InO exposure did not influence PFS (hazard ratio, 1.20; 95% confidence interval, 0.71-2.03) in multivariate models. Within InO-exposed patients, InO responders had superior PFS (P = .002) and OS (P < .0001) relative to InO-refractory patients. The timing of administering InO did not affect brexu-cel outcomes, with comparable PFS (P = .51) and OS (P = .86) for patients receiving InO as bridging therapy or before apheresis. In conclusion, although InO exposure was associated with inferior survival outcomes after brexu-cel in unadjusted analyses, these associations were no longer significant in multivariate analyses, suggesting it is unlikely that InO negatively affects brexu-cel efficacy. Our data instead imply that InO-exposed recipients of brexu-cel tend to be higher-risk patients with intrinsic adverse leukemia biology.
Gender Differences in Autonomy Granted to Residents and Fellows During Procedural Training: A Systematic Review and Meta-Analysis
Lund, Sarah , Griffeth, Elaine M. , Williamson, Andrea J.H. , Collings, Amelia T. , Gudmundsdottir, Hallbera , Han, Amy , Kearse, LaDonna , Kratzke, Ian M. , Wilkins, Parvathi , Prokop, Larry J. , Cook, David A. , Williamson, Andrea , Collings, Amelia , Prokop, Larry , Kearse, LaDonna E , Gudmundsdottir, Hallbera

Mayo Clinic

Academic Medicine | August 2, 2024 | Volume: 99 | Issue: 8 | Pages: 922-930

10.1097/acm.0000000000005673 | PMID 38412483 Get It

Abstract Purpose Supervisors may be prone to implicit (unintentional) bias when granting procedural autonomy to trainees due to the subjectivity of autonomy decisions. The authors aimed to conduct a systematic review and meta-analysis to assess the differences in perceptions of procedural autonomy granted to physician trainees based on gender and/or race. Method MEDLINE, Embase, CENTRAL, Scopus, and Web of Science were searched (search date: January 5, 2022) for studies reporting quantitative gender- or race-based differences in perceptions of procedural autonomy of physician trainees. Reviewers worked in duplicate for article selection and data abstraction. Primary measures of interest were self-reported and observer-rated procedural autonomy. Meta-analysis pooled differences in perceptions of procedural autonomy based on trainee gender. Results The search returned 2,714 articles, of which 16 were eligible for inclusion. These reported data for 6,109 trainees (median, 90 per study) and 2,763 supervisors (median, 54 per study). No studies investigated differences in perceptions of autonomy based on race. In meta-analysis of disparities between genders in autonomy ratings (positive number favoring female trainees), pooled standardized mean differences were −0.12 (95% confidence interval [CI], −0.19 to −0.04; P = .003; n = 10 studies) for trainee self-rated autonomy and −0.05 (95% CI, −0.11 to 0.01; P = .07; n = 9 studies) for supervisor ratings of autonomy. Conclusions Limited evidence suggests that female trainees perceived that they received less procedural autonomy than did males. Further research exploring the degree of gender- and race-based differences in procedural autonomy, and factors that influence these differences is warranted.
Oncology stewardship practice in the United States: A Hematology/Oncology Pharmacy Association national survey
Banez, Marisela Tan , Atienza, Sol , Butts, Allison R, Derba, Megan, Dicke, Katie, Haverstick, Kimberly, Heron, Bernadette B. , Cimino, Sarah K, Loop, Matthew Shane , Hough, Shannon , Merten, Julianna A., Taucher, Kate D, Zhang, J, Butts, Allison , Shah, Vishal , Mahmoudjafari, Zahra , Moore, Donald C. , Shah, Vishal

Mayo Clinic

Journal of Oncology Pharmacy Practice | August 2, 2024 | Volume: 31 | Issue: 4 | Pages: 517-527

10.1177/10781552241265280 | PMID 39091073 Get It

Introduction The treatment of cancer is associated with high risk for toxicity and high cost. Strategies to enhance the value, quality, and safety of cancer care are often managed independently of one another. Oncology stewardship is a potential framework to unify these efforts and enhance outcomes. This landscape survey establishes baseline information on oncology stewardship in the United States. Methods The Hematology/Oncology Pharmacy Association (HOPA) distributed a 38-item survey composed of demographic, institutional, clinical decision-making, support staff, metrics, and technology sections to 675 HOPA members between 9 September 2022 and 9 October 2022. Results Most organizations (78%) have adopted general pharmacy stewardship practices; however, only 31% reported having established a formalized oncology stewardship team. More than 70% of respondents reported implementation of biosimilars, formulary management, and dose rounding as oncology stewardship initiatives in both inpatient and outpatient settings. Frequently cited barriers to oncology stewardship included lack of clinical pharmacist availability (74%), lack of oncology stewardship training (62%), lack of physician/provider buy-in (32%), and lack of cost-saving metrics (33%). Only 6.6% of survey respondents reported their organization had defined “value in oncology.” Lack of a formalized stewardship program was most often cited (77%) as the rationale for not defining value. Conclusions Less than one-third of respondents have established oncology stewardship programs; however, most are providing oncology stewardship practices. This manuscript serves as a call to action for stakeholders to work together to formalize oncology stewardship programs that optimize value, quality, and safety for patients with cancer.
Association Between Frailty Status and Readmissions in Hospitalized Patients With Systemic Lupus Erythematosus
Leung, Christopher , Tahir, Waqas , Rosli, Yenny Y., Lieber, Sarah B. , Makris, Una E. , Ali, Hammad , Singh, Siddharth , Ali, Hammad , Goulabchand, Radjiv , Singh, Namrata , Makris, Una E , Leung, Christopher, Tahir, Waqas, Lee, Jiha

Mayo Clinic

ACR Open Rheumatology | July 29, 2024 | Volume: 6 | Issue: 10 | Pages: 700-706

10.1002/acr2.11722 | PMID 39074031 Get It

ObjectiveThe objective of this study was to evaluate the association between frailty status and risk of readmissions, inpatient death, and cost of admission among patients with systemic lupus erythematosus (SLE).MethodsWe conducted a retrospective cohort study using the National Readmissions Database. Using International Statistical Classification of Diseases, Tenth Revision codes, we identified individuals >18 years of age who had a primary or secondary diagnosis of SLE and were hospitalized between January and June 2018. Using the validated claims‐based Hospital Frailty Risk Score, we categorized individuals as frail (score ≥ 5) or nonfrail (score < 5) at the time of index hospitalization. Our primary outcome was readmission rates post discharge from index hospitalization. Secondary outcomes were rates of inpatient mortality and the total cost of hospitalizations. Cox proportional hazard models were used to estimate the association between frailty and risk of readmissions, with adjustment for age, sex, insurance type, household income, and Elixhauser Comorbidity Index score.ResultsA total of 39,738 patients with SLE met eligibility criteria. Over a median follow‐up of eight months, frail patients with SLE (n = 18,385) had higher Elixhauser Comorbidity Index scores and longer length of stay compared to nonfrail patients with SLE (n = 21,353). Frail patients with SLE had higher readmission rates, a higher proportion of prolonged hospitalizations, and higher costs per hospitalization. Frailty was independently associated with a 10% higher risk of readmission after adjustment for covariates.ConclusionAmong hospitalized adults with SLE, presence of frailty was associated with higher readmission and inpatient mortality rates. Our results highlight that frailty status can help risk stratify patients with SLE at increased risk for readmissions and other adverse health outcomes.
Central α2‐adrenergic mechanisms regulate human sympathetic neuronal discharge strategies
Klassen, Stephen A. , Limberg, Jacqueline K. , Iannarelli, Nathaniel , Senefeld, Jonathon W. , Nicholson, Wayne T. , Joyner, Michael J. , Shoemaker, J. Kevin , Curry, Timothy B. , Shoemaker, J Kevin , Joyner, Michael J , Senefeld, Jonathon W , Klassen, Stephen A , Harvey, Ronée E. , Wiggins, Chad C. , Baker, Sarah E.

Mayo Clinic

The Journal of Physiology | July 26, 2024 | Volume: 602 | Issue: 16 | Pages: 4053-4071

10.1113/jp286450 | PMID 39058701 Get It

AbstractThe present study investigated the impact of central α2‐adrenergic mechanisms on sympathetic action potential (AP) discharge, recruitment and latency strategies. We used the microneurographic technique to record muscle sympathetic nerve activity and a continuous wavelet transform to investigate postganglionic sympathetic AP firing during a baseline condition and an infusion of a α2‐adrenergic receptor agonist, dexmedetomidine (10 min loading infusion of 0.225 µg kg−1; maintenance infusion of 0.1–0.5 µg kg h−1) in eight healthy individuals (28 ± 7 years, five females). Dexmedetomidine reduced mean pressure (92 ± 7 to 80 ± 8 mmHg, P < 0.001) but did not alter heart rate (61 ± 13 to 60 ± 14 bpm; P = 0.748). Dexmedetomidine reduced sympathetic AP discharge (126 ± 73 to 27 ± 24 AP 100 beats−1, P = 0.003) most strongly for medium‐sized APs (normalized cluster 2: 21 ± 10 to 5 ± 5 AP 100 beats−1; P < 0.001). Dexmedetomidine progressively de‐recruited sympathetic APs beginning with the largest AP clusters (12 ± 3 to 7 ± 2 clusters, P = 0.002). Despite de‐recruiting large AP clusters with shorter latencies, dexmedetomidine reduced AP latency across remaining clusters (1.18 ± 0.12 to 1.13 ± 0.13 s, P = 0.002). A subset of six participants performed a Valsalva manoeuvre (20 s, 40 mmHg) during baseline and the dexmedetomidine infusion. Compared to baseline, AP discharge (Δ 361 ± 292 to Δ 113 ± 155 AP 100 beats−1, P = 0.011) and AP cluster recruitment elicited by the Valsalva manoeuvre were lower during dexmedetomidine (Δ 2 ± 1 to Δ 0 ± 2 AP clusters, P = 0.041). The reduction in sympathetic AP latency elicited by the Valsalva manoeuvre was not affected by dexmedetomidine (Δ –0.09 ± 0.07 to Δ –0.07 ± 0.14 s, P = 0.606). Dexmedetomidine reduced baroreflex gain, most strongly for medium‐sized APs (normalized cluster 2: –6.0 ± 5 to –1.6 ± 2 % mmHg−1; P = 0.008). These data suggest that α2‐adrenergic mechanisms within the central nervous system modulate sympathetic postganglionic neuronal discharge, recruitment and latency strategies in humans. imageKey points Sympathetic postganglionic neuronal subpopulations innervating the human circulation exhibit complex patterns of discharge, recruitment and latency. However, the central neural mechanisms governing sympathetic postganglionic discharge remain unclear. This microneurographic study investigated the impact of a dexmedetomidine infusion (α2‐adrenergic receptor agonist) on muscle sympathetic postganglionic action potential (AP) discharge, recruitment and latency patterns. Dexmedetomidine infusion inhibited the recruitment of large and fast conducting sympathetic APs and attenuated the discharge of medium sized sympathetic APs that fired during resting conditions and the Valsalva manoeuvre. Dexmedetomidine infusion elicited shorter sympathetic AP latencies during resting conditions but did not affect the reductions in latency that occurred during the Valsalva manoeuvre. These data suggest that α2‐adrenergic mechanisms within the central nervous system modulate sympathetic postganglionic neuronal discharge, recruitment and latency strategies in humans.
NCCN Guidelines® Insights: Melanoma: Cutaneous, Version 2.2024
Johnson, Douglas B. , Albertini, Mark R. , Barker, Christopher A. , Bateni, Sarah B. , Baumgartner, Joel , Bichakjian, Christopher K. , Chandra, Sunandana , DiMaio, Dominick J. , Dronca, Roxana , Fleming, Martin D. , Galan, Anjela , Guild, Samantha, Hyngstrom, John , Karakousis, Giorgos C. , Kendra, Kari , Lange, Julie R., Lanning, Ryan M. , Logan, Theodore F. , Ott, Patrick A. , Ross, Merrick I. , Skitzki, Joseph J. , Smith, Emily , Tsai, Katy K., Wuthrick, Evan , Xing, Yan, McMillian, Nicole R., Espinosa, Sara, Olson, Daniel J. , Swetter, Susan M. , Bhatia, Shailender , Boland, Genevieve M. , Chmielowski, Bartosz , Fields, Ryan C. , Kiuru, Maija H. , Olson, Daniel, Olszanski, Anthony J. , Rothermel, Luke D. , Salama, April K.S. , Sharma, Rohit R. , Xing, Yan

Mayo Clinic

Journal of the National Comprehensive Cancer Network | July 26, 2024 | Volume: 22 | Issue: 5 | Pages: 290-298

10.6004/jnccn.2024.0036 | PMID 39019054 Get It

The NCCN Guidelines for Cutaneous Melanoma (termed Melanoma: Cutaneous ) provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients. These NCCN Guidelines Insights focus on the update to neoadjuvant systemic therapy options and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Cutaneous Melanoma.
Direct Comparison of Methods to Differentiate Wide Complex Tachycardias: Novel Automated Algorithms Versus Manual ECG Interpretation Approaches
LoCoco, Sarah , Kashou, Anthony H. , Deshmukh, Abhishek , Asirvatham, Samuel J. , DeSimone, Christopher V. , Mikhova, Krasimira M., Sodhi, Sandeep , Cuculich, Phillip S. , Ghadban, Rugheed , Cooper, Daniel , Deshmukh, Abhishek J , Sodhi, Sandeep S , Maddox, Thomas M , Noseworthy, Peter A , May, Adam M , Asirvatham, Samuel J , DeSimone, Christopher V , Noseworthy, Peter A. , May, Adam M.

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | July 25, 2024 | Volume: 17 | Issue: 8 | Pages: No page available

10.1161/circep.123.012663 | PMID 39051111 Get It

BACKGROUND: Differentiating wide complex tachycardias (WCTs) into ventricular tachycardia (VT) and supraventricular wide tachycardia via 12-lead ECG interpretation is a crucial but difficult task. Automated algorithms show promise as alternatives to manual ECG interpretation, but direct comparison of their diagnostic performance has not been undertaken. METHODS: Two electrophysiologists applied 3 manual WCT differentiation approaches (ie, Brugada, Vereckei aVR, and VT score). Simultaneously, computerized data from paired WCT and baseline ECGs were processed by 5 automated WCT differentiation algorithms (WCT Formula, WCT Formula II, VT Prediction Model, Solo Model, and Paired Model). The diagnostic performance of automated algorithms was compared with manual ECG interpretation approaches. RESULTS: A total of 212 WCTs (111 VT and 101 supraventricular wide tachycardia) from 104 patients were analyzed. WCT Formula demonstrated superior accuracy (85.8%) and specificity (87.1%) compared with Brugada (75.2% and 57.4%, respectively) and Vereckei aVR (65.3% and 36.4%, respectively). WCT Formula II achieved higher accuracy (89.6%) and specificity (85.1%) against Brugada and Vereckei aVR. Performance metrics of the WCT Formula (accuracy 85.8%, sensitivity 84.7%, and specificity 87.1%) and WCT Formula II (accuracy 89.8%, sensitivity 89.6%, and specificity 85.1%) were similar to the VT score (accuracy 84.4%, sensitivity 93.8%, and specificity 74.2%). Paired Model was superior to Brugada in accuracy (89.6% versus 75.2%), specificity (97.0% versus 57.4%), and F1 score (0.89 versus 0.80). Paired Model surpassed Vereckei aVR in accuracy (89.6% versus 65.3%), specificity (97.0% versus 75.2%), and F1 score (0.89 versus 0.74). Paired Model demonstrated similar accuracy (89.6% versus 84.4%), inferior sensitivity (79.3% versus 93.8%), but superior specificity (97.0% versus 74.2%) to the VT score. Solo Model and VT Prediction Model accuracy (82.5% and 77.4%, respectively) was superior to the Vereckei aVR (65.3%) but similar to Brugada (75.2%) and the VT score (84.4%). CONCLUSIONS: Automated WCT differentiation algorithms demonstrated favorable diagnostic performance compared with traditional manual ECG interpretation approaches.
Leveraging management engineering and business consulting for rapid response, mitigation and recovery during a pandemic
Hoover, Michele R., Kamath, Janine R., Dhanorker, Sarah R., Schieffer, Chris, Macken, Carolyn M., Donahoe-Anshus, Amerett L., Chihak, Anthony A.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 6 | Issue: 1 | Pages: 32

10.69554/twre6225 Get It

The novel severe acute respiratory syndrome coronavirus 2, which causes coronavirus disease 2019 (COVID-19), has presented healthcare delivery challenges the world has never encountered before. Healthcare and its practitioners, while finding themselves in difficult situations, must still care for patients with emergent needs and ensure the safety and well-being of all patients and staff. At Mayo Clinic, effective navigation of the dynamic and complex situation created by COVID-19 required unique multidisciplinary collaborations to design and implement solutions quickly. Frontline care providers and staff of ancillary services and other critical healthcare functions partnered with the Department of Management Engineering and Consulting (ME&C) team to organise and re-engineer operations to iteratively adapt to the dynamic ‘new normal’. Health systems engineers (HSEs) and project managers (PMs) accelerated the implementation of innovative interventions by leveraging advanced engineering and consulting frameworks, models and methods. Utilising a patient and staff-centric systems approach to align electronic systems, operational processes, staffing resources and organisational infrastructure has been invaluable for speed and effectiveness. Harnessing the promise of digital technology and advanced analytics was imperative and set the stage for a broader set of possibilities to transform healthcare. These possibilities include scaling of consumerfocused virtual services in multiple and unfamiliar settings, new assets that could be reused for future emergencies, accelerating the implementation of time-sensitive solutions, applied analytics and modelling to predict clinical, financial and community impacts and reimaging the healthcare supply chain. As more has been learned about the trajectory and management of COVID-19, the need to rapidly evolve and pivot interventions for short-, medium-, and long-term applications continues. This article addresses the unique contributions of ME&C during the COVID-19 crisis and the results-oriented collaborations with staff in critical business functions. We believe that the experiences, outcomes and lessons learned through this journey are broadly transferable to other healthcare and nonhealthcare organisations.
Talent mobility for accelerating diversity at leadership levels: A pilot study
Kamath, Janine R., Dhanorker, Sarah R.

Mayo Clinic

Management in Healthcare: A Peer-Reviewed Journal | July 25, 2024 | Volume: 8 | Issue: 2 | Pages: 156

10.69554/mriy5207 Get It

Mayo Clinic is committed to reskilling and upskilling its workforce and to creating a strong, diverse leadership pipeline to advance its ‘Bold. Forward.’ strategy. In alignment with this commitment, the Mayo Clinic Shared Services Organization (MCSSO) launched a pilot offering staff the opportunity to work in a hybrid role and build new skills and connections. Pilot participants split their time equally between job roles in which the professional skill sets required were approximately the same. The pilot involved six MCSSO departments and six candidates (three pairs) from the participating departments. Staff were recruited for three roles: senior project manager, senior business analyst and call centre representative. Each of the three pairs worked in a hybrid assignment for six months. Candidates were offered opportunities to network with each other, MCSSO senior leaders and other diverse colleagues. Pilot evaluations were conducted at 0, 3 and 6 months with candidates and their supervisors. Additionally, benchmarking with external organisations allowed learning from advanced talent mobility and leadership diversity programmes. The evaluations highlighted that 50 per cent of the candidates were promoted by the end of their hybrid assignment. Most of them engaged in new projects, cross-trained and gained valuable insights, skills and expertise. Candidates and supervisors valued the opportunity to network with senior leaders and cross-functional colleagues. The pilot and external benchmarks emphasised the importance of a formal ‘talent mobility programme’ to build and sustain a diverse leadership pipeline. It is crucial to be intentional and bold with hybrid and mobility opportunities for intersectional candidates, under-represented groups and staff committed to equity, inclusion and diversity. All candidates and supervisors wanted the pilot to be expanded and operationalised. We believe that these early experiences, results and lessons on preparing diverse talent for leadership levels in the organisation are broadly transferable to other healthcare and non-healthcare organisations.
Pulmonary complications of advanced chronic liver diseases: an updated review
Thévenot, Thierry , Raevens, Sarah , Aujayeb, Avinash , Banini, Bubu A. , Cadranel, J.F. , DuBrock, Hilary M. , DuBrock, Hilary M , Aujayeb, Avinash

Mayo Clinic

Exploration of Digestive Diseases | July 25, 2024 | Volume: No volume available | Issue: No issue available | Pages: 301-325

10.37349/edd.2024.00053 Get It

Patients with advanced chronic liver disease can develop specific pulmonary complications related or unrelated to pre-existing lung disease. The three major pulmonary complications in this patient population include hepatopulmonary syndrome (HPS), portopulmonary hypertension (PoPH), and hepatic hydrothorax (HH). These entities are most often revealed by increasing dyspnea together with signs of portal hypertension. The prevalence of these complications remains underestimated due to the lack of routine screening of the cirrhotic population. The pathophysiology of HH is better understood than that of HPS and PoPH. The clinical features, diagnosis, and therapeutic options of these pulmonary complications are extensively discussed in this chapter. Liver transplantation may offer a curative therapy in highly-selected cases and MELD exception points allow priority access to liver transplantation, thus avoiding potential deterioration while awaiting transplant and providing a better post liver transplant survival. The complexity of managing these pulmonary complications requires a multidisciplinary team approach, especially when liver transplantation is indicated.